X-ZELL named Deep Tech Pioneer by Hello Tomorrow

Singapore, November 2019 – On the back of qualifying for the regional final of the prestigious Hello Tomorrow Challenge, X-ZELL has now been selected as one of Hello Tomorrow’s Deep Tech Pioneers.

According to the competition’s organising committee, it received a record-breaking 5,000+ applications from 128 countries for the Challenge, with X-ZELL not only qualifying as a regional finalist for the Southeast Asia cohort, but also making the shortlist for the global showdown next March in Paris.

“Being a Deep Tech Pioneer means that X-ZELL has been recognised by Hello Tomorrow as one of the most promising projects in deep tech to date,” the committee explained – adding that the final selection for the Paris event  will be made in January.

One of the world’s leading deep tech start-up competitions, the Hello Tomorrow Challenge was created to celebrate the best and brightest breakthrough solutions made possible with science and technology.

The goal is to provide innovative ideas with the resources, energy and network required to make them a reality and bring positive change to our planet.

The global Hello Tomorrow Challenge Finale will be held as part of the highly anticipated Hello Tomorrow Summit in Paris, France from 10-13 March 2020..

Date:               10-13 Mar 2020
Venue:            The Centquatre, Paris, FRA
More:              www.hello-tomorrow.org

Media Contact:
Sebastian Grote
Head of Strategy, Marketing & Communications
+65 9630 0706


About X-ZELL
Recurrently ranked among the most innovative health technology start-ups in Asia, X-ZELL is fusing next-generation cell detection technology with cutting-edge Artificial Intelligence to isolate and visualise ultra-rare cells in blood and frozen tissue. Established in Bangkok, Thailand, the company recently made global headlines when it demonstrated the ability to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in small, 10mL blood samples. Widely considered one of the most promising biomarkers for the early detection of clinically significant cancers, tCEC had previously been classified as undetectable in clinical routine. Now headquartered in Singapore, X-ZELL is aiming to make tCEC-based cancer screening accessible to patients around the globe – making the young company one of the promising names in the booming cancer prevention space.

About Hello Tomorrow
Hello Tomorrow is a global non-profit on a mission to accelerate deep technology research and entrepreneurship, and to bring breakthrough innovation to commercial scale. Headquartered in Paris, France, the organisation can draw on a network of six regional hubs around the world as well as a global grassroots community. ​The Hello Tomorrow Global Challenge is considered the largest deep-tech start-up competition in the world.


Next-generation cytology

© 2023 X-ZELL INC

Find Us